NEW CHALCONE COMPOUND EXHIBITS MICRORNA-MEDIATED ANTICANCER PROPERTIES IN GLIOBLASTOMA

This study sought to investigate the therapeutic efficacy of a new synthetic chalcone molecule, SHG-44, its cellular mechanistic actions, alongside its effects on the miRNome in U87MG and U251 glioblastoma cell line models. Our research hypothesis stated that SHG-44 would exhibit significant anti-cancer properties by modulating miRNA expression within glioblastoma cells. To test this hypothesis, we conducted small RNA sequencing (sRNA-seq) to compare miRNA expression profiles between a control group (treated with 1% DMSO) and a treated group (treated with 100µM SHG-44) in U87MG glioblastoma cells. The resulting data revealed a list of deregulated miRNAs in the presence of SHG-44, with the logFC2 values indicating the degree of upregulation or downregulation of these miRNAs compared to the DMSO control group. Our data showed that SHG-44 significantly altered the expression of various miRNAs, suggesting a potential mechanism by which this compound exerts its anti-cancer effects. Notable findings include the identification of several miRNAs that were markedly upregulated or downregulated, which could be key players in the regulatory pathways affected by SHG-44. The data can be interpreted as evidence that SHG-44 modulates miRNA expression, thereby impacting cellular pathways crucial for glioblastoma cell survival and proliferation. This detailed analysis enables other researchers to understand the specific miRNAs affected by SHG-44 and provides a basis for further investigation into the molecular mechanisms underlying its therapeutic potential.